The pooled effects showed no significant difference in the rate of COVID-19 hospitalization (RR: 0.82; 95% CI: 0.36-1.85; P = 0.64) (Figure 3B) between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics. The gene discussed is IL17A; the disease is COVID-19.